These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 38204163)
1. Application of improved GalNAc conjugation in development of cost-effective siRNA therapies targeting cardiovascular diseases. Li Q; Yin K; Ma HP; Liu HH; Li S; Luo X; Hu R; Zhang WW; Lv ZS; Niu XL; Gu MH; Li CL; Liu YS; Liu YJ; Li HB; Li N; Li C; Gu WW; Li JJ Mol Ther; 2024 Mar; 32(3):637-645. PubMed ID: 38204163 [TBL] [Abstract][Full Text] [Related]
6. In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters. Ramsden D; Wu JT; Zerler B; Iqbal S; Jiang J; Clausen V; Aluri K; Gu Y; Dennin S; Kim J; Chong S Drug Metab Dispos; 2019 Oct; 47(10):1183-1194. PubMed ID: 31270142 [TBL] [Abstract][Full Text] [Related]
7. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198 [TBL] [Abstract][Full Text] [Related]
8. Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates. Foster DJ; Brown CR; Shaikh S; Trapp C; Schlegel MK; Qian K; Sehgal A; Rajeev KG; Jadhav V; Manoharan M; Kuchimanchi S; Maier MA; Milstein S Mol Ther; 2018 Mar; 26(3):708-717. PubMed ID: 29456020 [TBL] [Abstract][Full Text] [Related]
9. Metabolically Stable Anomeric Linkages Containing GalNAc-siRNA Conjugates: An Interplay among ASGPR, Glycosidase, and RISC Pathways. Kandasamy P; Mori S; Matsuda S; Erande N; Datta D; Willoughby JLS; Taneja N; O'Shea J; Bisbe A; Manoharan RM; Yucius K; Nguyen T; Indrakanti R; Gupta S; Gilbert JA; Racie T; Chan A; Liu J; Hutabarat R; Nair JK; Charisse K; Maier MA; Rajeev KG; Egli M; Manoharan M J Med Chem; 2023 Feb; 66(4):2506-2523. PubMed ID: 36757090 [TBL] [Abstract][Full Text] [Related]
10. Less Is More: Novel Hepatocyte-Targeted siRNA Conjugates for Treatment of Liver-Related Disorders. Weingärtner A; Bethge L; Weiss L; Sternberger M; Lindholm MW Mol Ther Nucleic Acids; 2020 Sep; 21():242-250. PubMed ID: 32590173 [TBL] [Abstract][Full Text] [Related]
11. Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate. Zimmermann TS; Karsten V; Chan A; Chiesa J; Boyce M; Bettencourt BR; Hutabarat R; Nochur S; Vaishnaw A; Gollob J Mol Ther; 2017 Jan; 25(1):71-78. PubMed ID: 28129130 [TBL] [Abstract][Full Text] [Related]
12. The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of McDougall R; Ramsden D; Agarwal S; Agarwal S; Aluri K; Arciprete M; Brown C; Castellanos-Rizaldos E; Charisse K; Chong S; Cichocki J; Fitzgerald K; Goel V; Gu Y; Guenther D; Habtemariam B; Jadhav V; Janas M; Jayaraman M; Kurz J; Li J; Liu J; Liu X; Liou S; Maclauchlin C; Maier M; Manoharan M; Nair JK; Robbie G; Schmidt K; Smith P; Theile C; Vaishnaw A; Waldron S; Xu Y; Zhang X; Zlatev I; Wu JT Drug Metab Dispos; 2022 Jun; 50(6):781-797. PubMed ID: 34154993 [TBL] [Abstract][Full Text] [Related]
13. Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs. Agarwal S; Allard R; Darcy J; Chigas S; Gu Y; Nguyen T; Bond S; Chong S; Wu JT; Janas MM Nucleic Acid Ther; 2021 Aug; 31(4):309-315. PubMed ID: 33861634 [TBL] [Abstract][Full Text] [Related]
14. Exposure to siRNA-GalNAc Conjugates in Systems of the Standard Test Battery for Genotoxicity. Janas MM; Jiang Y; Duncan RG; Hayes AN; Liu J; Kasperkovitz PV; Placke ME; Barros SA Nucleic Acid Ther; 2016 Dec; 26(6):363-371. PubMed ID: 27387336 [TBL] [Abstract][Full Text] [Related]